PROC
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer (NCT07741630) | Peking University Third Hospital | 2026-08-15 |
| A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. (NCT07470853) | Whitehawk Therapeutics, Inc. | 2026-03-15 |
| Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors (NCT07444814) | Whitehawk Therapeutics, Inc. | 2025-12-19 |
Track PROC automatically
Every clearance here is in the API, with alerts when new ones post.